null Research suggests greater access to specific HIV and tuberculosis medications is needed worldwide
Postdoctoral fellows at the RI-MUHC carried out primary statistical analyses for study published in The Lancet
Aug. 24, 2020
Source: Med E-News. Researchers at the Research Institute of the McGill University Health Centre (RI-MUHC) played an important role in a recent study led by the Perelman School of Medicine at the University of Pennsylvania, that found that implementing a combination of antiretroviral therapy (ART) for HIV and newer tuberculosis medications decreased the risk of death for adults with multidrug-resistant TB. The findings, which were published this month in The Lancet, suggest that every effort should be made to quickly bring these life-saving medications to those in need.
The data, managed by Dr. Dick Menzies, a senior scientist at the RI-MUHC, was from over 100 different investigators. The database, originally compiled some 10 years ago and updated on a near annual basis, has previously been used to inform WHO guidelines and perform other timely analyses for multidrug-resistant TB. For this latest study, the primary statistical analyses were carried out by RI-MUHC postdoctoral fellows Mayara Bastos, PhD, and Jonathon Campbell, PhD. Ultimately, using data from 52 studies and 37 different countries, the investigators controlled for variables like age, the wealth of the region in which the individuals lived, and severity of drug resistance.